12/08/2026
Advancing the future of precision cancer care, one conversation at a time.
The Medicaid Cancer Foundation, in collaboration with the Oncidium Foundation, was proud to host the Virtual Radiotheranostics Summit a platform that brought together leading experts, clinicians, researchers, and healthcare professionals to explore the latest advancements in radiotheranostics and precision oncology.
The summit highlighted the growing impact of Lutetium-177 (Lu-177) radioligand therapy in the treatment of advanced prostate cancer and neuroendocrine tumors, while showcasing real-world clinical experiences from Nigeria. Discussions also focused on expanding access to these innovative therapies through stronger collaborations, early referrals, investment in healthcare infrastructure, and continued medical education.
As precision medicine continues to transform cancer care, conversations like these are essential to driving innovation, strengthening healthcare systems, and ensuring that more patients across Africa have access to life changing treatments.
Together with our partners, we remain committed to creating platforms that inspire learning, foster collaboration, and contribute to a future where equitable, high quality cancer care is within reach for all.